Funding Opportunities

Due Dates: October 11, 2023

Open Date: Earliest Submission Date: September 11, 2023

The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.   

More information here

Open Date (Earliest Submission Date): February 05, 2023

Expiration Date: January 08, 2026

The purpose of this Notice of Special Interest (NOSI) is to highlight NIAID’s interest in accepting applications that aim to understand the critical drivers of Tuberculosis (TB) transmission at the individual and population levels in high-burden settings. Applicants are encouraged to develop effective methods to measure rates of TB transmission that rely on an increased understanding of the biomedical basis of transmission and related risk factors and to develop and assess potential interventions, including low-cost and low-tech options, to prevent TB transmission.

For more information click here

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. Concepts reveal possible initiatives or give you ideas for an investigator-initiated application.

Analyzing Early Events in Tuberculosis (TB) and TB/HIV Infection To Identify Interventional Targets

Request for Applications—proposed FY 2024 initiative

Objective: Early events associated with Mycobacterium tuberculosis (Mtb) infection are not well understood. However, studies delineating the initial stage of Mtb infection may identify unique targets for more effective vaccine adjuvants and immunomodulators, as well as improved biomarkers to advance prevention and therapy of TB. The objectives of this initiative are to better understand how Mtb evades and disrupts host immunity at the earliest stages of infection, and how myeloid (macrophages, dendritic cells, eosinophils), lymphoid (T cells, B cells, innate lymphoid cells) and non-immune cells (alveolar epithelial cells, pneumocytes, vascular) in the airway and lung interact with Mtb and each other. Furthermore, delineating the effects of HIV co-infection on immune mechanisms during early Mtb infection will facilitate the development of effective immune-based interventions for people living with HIV.

Contact: 
Robert Mahon
robert.mahon@nih.gov

Consortium for Design of TB Drug Regimens

Request for Applications—proposed FY 2024 initiative

Objective: To establish a consortium of tuberculosis (TB) preclinical and clinical experts to systematically refine preclinical models with clinical data and identify the most efficacious combination regimens for future clinical testing to optimize relapse-free TB treatment.

Contact:
Barbara Laughon
blaughon@mail.nih.gov

Mycobacterium tuberculosis Quality Assessment (TBQA) Program

Request for Proposals—proposed FY 2024 initiative

Objective: TBQA will 1) support the ability of laboratories to reliably perform study-specified Mycobacterium tuberculosis (Mtb) tests; 2) evaluate Mtb technologies and specimen processes for use in clinical investigations; 3) disseminate technical and scientific data; 4) perform late-stage assay validation and/or Mtb assay testing of clinical samples in a CLIA-certified laboratory (Option); and 5) support public health emergency needs (Option). The TBQA will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States. Examples of NIAID-sponsored Networks include the Adult AIDS Clinical Trials Group (ACTG), the International Maternal Pediatric and Adolescent AIDS Clinical Trials Group (IMPAACT), and the HIV Vaccine Trials Network (HVTN). Examples of NIAID-sponsored TB cohorts include the India and Brazil Regional Prospective Observational Research for Tuberculosis (RePORT).

Contact: 
Isaac Elliott
isaac.elliott@nih.gov

You can find more information here

NIAID 2022 OMNIBUS BROAD AGENCY ANNOUNCEMENT (BAA) NO. HHS-NIH-NIAID-BAA2022-1 contains four (4) distinct Research Areas, each with specified closing date and time.   The proposal due date of March 18, 2022, specified in this solicitation posting, is the due date for Research Area 003 only.  An Amendment will be issued at a later date to update the proposal due date for responses to Research Areas 001, 002, 004.  The proposal due dates for each Research Area are identified below:

Research Area 001 - Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases 

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 002 - Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

Research Area 003 - The Antiviral Program for Pandemics (APP): Development of Antivirals for Specific RNA Viral Families of Pandemic Potential

Proposals Due Date and Time - 3:00 PM Eastern Time on March 18, 2022

Research Area 004 - Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections (AMR), and Emerging Infectious Diseases

Proposals Due Date and Time - 3:00 PM Eastern Time on April 18, 2022

For more information click HERE!!

Solicitation for BAA-DAIT-75N93021R00008 entitled, "Advancing Vaccine Adjuvant Research for Tuberculosis (TB)"

Contract Opportunity Type: Solicitation
 

The goal of this program is to further the development of TB vaccines through sideby-side comparisons of adjuvants in combination with TB immunogens, and to establish immunological profiles of adjuvants that work through different mechanisms, facilitating the identification of the most promising adjuvant:Mtb immunogen candidates for clinical development and potential immune correlates of protection. The range of adjuvants to be evaluated may include novel classes of adjuvants being developed for other infections and immune-oncology therapeutics, as well as adjuvants already being developed for TB vaccines. It is anticipated that one cost reimbursement, completion type contract will be awarded for a five [5]-year period of performance beginning on or about 7/22/22.
NIAID anticipates that the average annual total cost (direct and indirect costs combined) is $4 million per contract. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five [5] years. Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about April, 28, 2021, and may be accessed through here. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

Published: Apr 28, 2021 12:41 pm EDT
Offers Due: Aug 10, 2021 03:00 pm EDT

Application Due Date: June 30, 2021. Letter of Intent Due Date: 30 days prior to the application due date.  Expires: July 01, 2021.

The purpose of this funding opportunity is to support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-007.html?utm_campaign=+46333793&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=

Application Due Date: June 15, 2021

The purpose of this Funding Opportunity Announcement (FOA) is to solicit meritorious applications for the Tuberculosis Research Advancement Centers (TRACs) program. The main goal of these centers is to provide administrative and shared research support to foster and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to New Investigators. TRACs will provide core facilities, services and mentoring opportunities to achieve the goals of the program.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-001.html

Application Due Date(s): January 11, 2021, and December 14, 2021

This funding opportunity announcement is intended to support research project grant (R01) applications that propose to utilize a syndemics (synergistic epidemic) framework to elucidate the role of social, economic, environmental, behavioral, structural, psychological factors in promoting the synergistic interactions and clustering of heart, lung, blood, and sleep (HLBS) comorbidities among people with HIV at the population level. The ultimate goal is to identify strategies that foster holistic approaches in the clinical management of people living with HIV who have HLBS comorbidities, and to utilize existing data to assess the feasibility and cost-effectiveness of such approaches.

https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-018.html

Application Due Date(s): February 22, 2021, All applications are due by 5:00 PM local time of applicant organization.

To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for the development of improved therapeutic approaches.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-057.html

Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. 

Request for Applications—proposed FY 2022 initiative

Understanding the Role of the M. Tuberculosis Granuloma in Tuberculosis (TB) Disease and Treatment Outcomes

Objective: To support research to better define the role of the granuloma, the hallmark structure of pulmonary tuberculosis (TB), in TB disease and disease outcomes. Improved understanding of the granuloma will provide a much-needed knowledge base for developing improved drugs, including host-directed therapies.

Contact: Karen Lacourciere

Tuberculosis Research Advancement Centers (TRACs)

Objective: To foster, support, and elevate multidisciplinary tuberculosis (TB) research and provide exceptional mentorship to early-career investigators at institutions with a concentration of TB researchers and a minimum TB funded research base (FRB).

Contact: Lakshmi Ramachandra

You can find more information in: https://www.niaid.nih.gov/grants-contracts/